ADCs (Antibody-Drug Conjugates)

The Integrated Guard for ADC Excellence

ADCs (Antibody-Drug Conjugates)

The ADC pipeline is exploding (100+ candidates globally), but success hinges on flawless execution across payload, linker, conjugation, and analytics. Fragmented vendors create blame-shifting "interface gaps," while DAR variability and linker instability derail programs. Aventiq Bio eliminates these risks with integrated oversight - leveraging India's emerging ADC powerhouse (single-use suites, advanced analytics) for faster, safer, and 40–60% more cost-effective development.

India - The Emerging ADC Powerhouse

India is rapidly positioning itself as a next-generation ADC hub, with 15+ facilities offering payload synthesis, linker chemistry, conjugation, and fill-finish - many featuring cutting-edge single-use conjugation suites for speed and sustainability. The sector is growing at 30%+ CAGR, supported by OEB 5 containment and increasing USFDA/EMA inspections. "China+1" strategies make it ideal for oncology innovators. Aventiq Bio provides vetted access to this capacity with seamless interface management.

Interface Gap & Vendor Fragmentation

Payload, mAb, and conjugation often split across vendors - leading to blame-shifting when hand-offs fail.
DAR Variability & Linker Instability

Inconsistent drug loading or cleavage profiles compromising efficacy and safety.
Cold-Chain Fragmentation

Degradation risks during transit between specialized sites.
Analytical Blind Spots

Inadequate methods for DAR distribution, free drug, or conjugate impurities - failing EMA/FDA scrutiny
Waste Management Liability

Environmental and regulatory exposure from "active" conjugated Cytotoxic Payloads

Integrated Oversight Across the ADC Lifecycle

We organize governance around the three critical pillars - ensuring seamless flow from potent Cytotoxic Payload to final conjugate.

Synthesis & Containment

HPAPI Governance: Independent oversight of cytotoxic "warhead" synthesis in OEB 5/6 high-containment environments.
Complex Synthetics: Technical mastery of Peptide linkers (Val-Cit-PABC) and next-gen Oligonucleotide payloads.
Intermediate Purity: Oversight of ultra-pure Linker-Payload assemblies to meet stringent limits for unconjugated species"

The Conjugation Bridge

Hand-off Logistics: Managing fragile cold-chain transitions between synthetic chemistry and bioprocessing sites.
Aggregation Mitigation: On-ground monitoring of stoichiometry and pH to prevent protein sticking
Fill-Finish Integrity: Validation of lyophilization cycles and light-protected primary packaging for long-term stability.

The Analytical Finality

DAR Distribution: Independent verification of Drug-to-Antibody Ratio using HIC-HPLC and SEC-MALS for potency consistency.
Impurity Profiling: Advanced characterization of unconjugated payloads and residual solvents (DMSO/DMF) post-purification.
Cleavage Kinetics: Governance of stability studies to ensure precise payload release only within the target cellular environment.

Extended Conjugated Modalities

Peptide–Drug Conjugates (PDCs):
Governance oversight across peptide linker–payload integration, stability, and controlled release—applying the same interface discipline used for ADC programs.

Radiopharmaceutical Conjugates (RDCs):
Advisory governance for radionuclide conjugation, radiochemical purity, and decay-kinetics management—ensuring safety, regulatory alignment, and data integrity.

Why Aventiq Bio – Your Integrated ADC Guardian

ADCs succeed or fail at the interface. The cytotoxic payload is a Highly Potent API; the antibody is a delicate biologic; the linker must hold and release with precision. Fragmented vendors create blame-shifting gaps. Aventiq Bio provides the single, independent thread of technical governance across payload synthesis, conjugation, analytics, and hand-offs — so the program stays on track, inspection-ready, and free of vendor bias.

What sets us apart:

Unique expertise at the HPAPI–biologics interface — we govern both the potent payload world and the conjugation/analytics world as one integrated program
Proprietary intelligence on payload (OEB 5/6), conjugation, and fill-finish facilities that can actually work together
Proven hand-off protocols that prevent DAR variability, free-drug issues, aggregation, and cold-chain failures between sites
Independent DAR verification, impurity profiling, and cleavage-kinetics oversight aligned with FDA / EMA expectations
True independence — your single thread of truth. No labs, no commissions, loyalty only to the sponsor's program

We accelerate oncology ADCs to clinic and approval by eliminating the interface gaps that traditionally derail these programs.

ADCs (Antibody-Drug Conjugates)